Sort   by:  
 Page size 
UnknownAssessment of Baseline Ultrawidefield Fluorescein Angiographic Quantitative Leakage Parameters with Ultrawidefield Fundus Features and Clinical Parameters in Diabetic Retinopathy in Protocol AA.
Not available
S-EPMC11868455 | biostudies-literature
UnknownAssessing the Effect of Personalized Diabetes Risk Assessments During Ophthalmologic Visits on Glycemic Control: A Randomized Clinical Trial.
Not available
S-EPMC4924347 | biostudies-literature
UnknownCost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema.
Not available
S-EPMC9896372 | biostudies-literature
UnknownLapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy: A Post Hoc Analysis of a Randomized Clinical Trial.
Not available
S-EPMC8532036 | biostudies-literature
UnknownAssociation of Predominantly Peripheral Lesions on Ultra-Widefield Imaging and the Risk of Diabetic Retinopathy Worsening Over Time.
Not available
S-EPMC9389433 | biostudies-literature
UnknownAssociation of Ultra-Widefield Fluorescein Angiography-Identified Retinal Nonperfusion and the Risk of Diabetic Retinopathy Worsening Over Time.
Not available
S-EPMC9389436 | biostudies-literature
UnknownPlasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
Not available
S-EPMC6568257 | biostudies-literature
UnknownIL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes.
Not available
S-EPMC8663550 | biostudies-literature
UnknownFour-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy.
Not available
S-EPMC10408259 | biostudies-literature
UnknownAflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.
Not available
S-EPMC9714135 | biostudies-literature
Sort   by:  
 Page size